UJ9.F SHANDONG BOAN BIOTECH.H 1
- Market cap
- EUR 212M
- P/E
- -
- P/B
- 0.60x
- ROE
- 0.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is UJ9.F undervalued?
Graham numberThe Graham number of SHANDONG BOAN BIOTECH.H 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SHANDONG BOAN BIOTECH.H 1 fundamental analysis
No fundamental analysis for SHANDONG BOAN BIOTECH.H 1 yet.
SHANDONG BOAN BIOTECH.H 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobu…
Full company profileSHANDONG BOAN BIOTECH.H 1 financial statements
SHANDONG BOAN BIOTECH.H 1 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 159M | 516M | 618M | 726M | 785M |
| Gross Profit | 107M | 354M | 409M | 543M | 562M |
| Operating Income | -217M | -326M | -104M | 104M | 40.6M |
| EBITDA | - | -246M | -22.5M | 179M | 134M |
| Net Income | -225M | -332M | -119M | 73.2M | 7.14M |
| EPS | -0.44 | -0.65 | -0.23 | 0.14 | 0.01 |
| Balance Sheet | |||||
| Total Assets | 2.11B | 2.20B | 2.32B | 2.85B | 4.13B |
| Total Liabilities | 555M | 784M | 1.00B | 1.21B | 1.39B |
| Shareholders' Equity | 1.55B | 1.42B | 1.32B | 1.64B | 2.74B |
| Cash & Short-term Investments | 614M | 233M | 202M | 199M | 1.13B |
| Cash Flow | |||||
| Operating Cash Flow | -246M | -202M | -18.6M | -118M | 64.9M |
| Capital Expenditure | 341M | 206M | 295M | 363M | 274M |
| Free Cash Flow | -588M | -408M | -313M | -481M | -209M |
| Ratios | |||||
| ROE | -14.5% | -23.4% | -9.0% | 4.5% | 0.3% |
| ROA | -10.7% | -15.1% | -5.1% | 2.6% | 0.2% |
| Net Profit Margin | -142.0% | -64.3% | -19.3% | 10.1% | 0.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SHANDONG BOAN BIOTECH.H 1 dividends
SHANDONG BOAN BIOTECH.H 1 has not paid dividends in the last 5 fiscal years.
Who owns SHANDONG BOAN BIOTECH.H 1
- Insiders 66.53%
- Institutions 3.70%
- Public & others 29.77%
- Shares outstanding 614M
- Free float 193M
SHANDONG BOAN BIOTECH.H 1 company profile
- Company name
- SHANDONG BOAN BIOTECH.H 1
- Ticker
- UJ9.F
- ISIN
- CNE100005RV4
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 690
- Fiscal year end
- December
- Address
- No. 39 Keji Avenue, Yantai, China
- Phone
- 86 53 5437 9111
- Website
- boan-bio.com
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal and male osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
SHANDONG BOAN BIOTECH.H 1 management
3- Ms. Hua JiangExecutive Chairlady & CEO · born 1978
- Mr. Shenghan WangCFO & Executive Director · born 1980
- Ms. Siu Kuen Lai FCIS, FCSCompany Secretary · born 1976